Phase 2-ready biotech developing small molecule therapies for CNS disorders.
Industry: Health Care
Latest Trade: $20.33 0.00 (0.0%)
First Day Return: +22.4%
Return from IPO: +19.6%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 05/17/2024 |
Offer Price | $17.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 8.0 |
Deal Size ($mm) | $136 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 06/06/2024 |
Offer Price | $17.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 8.0 |
Deal Size ($mm) | $136 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Goldman Sachs |
Jefferies |
more |
Company Data | |
---|---|
Headquarters | Boston, MA, United States |
Founded | 2022 |
Employees at IPO | 58 |
Website www.rapportrx.com |